- Email: [email protected]
Exam 1: Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:e25– e26
CME Activities–Exams 1 and 2 C. Mel Wilcox, MD, Editor, CME Section
CME Credits: The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AGA Institute designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any relevant financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Instructions: Category 1 credit can be earned by reading the relevant articles and taking these CME examinations online at http://www.cghjournal. org/content/cme. Answers can be obtained online after completing the exam(s).
Objectives: See article for specific learning objective.
e26
CME ACTIVITIES
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 3
Exam 1: Patients With Nondysplastic Barrett’s Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma Test ID No.: 0125
Contact Hours: 1.0
Expiration Date: March 31, 2012
Question 1: While prior studies have shown an increased rate of esophageal cancer in patients with Barrett’s esophagus, the number of patients with progression through dysplasia to cancer is widely variable. Such rates per year in the literature vary from:
a. b. c. d.
0%–1% 0.2%–3.5% 3%–5% 3.5%– 8%
a. b. c. d. e.
Race Age Severity of heartburn Length of Barrett’s esophagus Gender
a. b. c. d.
0% 2.7% 3.48% 0.78%
a. b. c. d.
0.2% 0.38% 0.21% 3.6%
Question 2: Which of the following was the only statistically significant predictor of histologic progression to dysplasia or cancer?
Question 3: In the study by Wani et al, the incident rate for development of esophageal adenocarcinoma was:
Question 4: In the study by Wani et al, the incident rate for low-grade dysplasia per year was:
CME Activities–Exams 1 and 2 C. Mel Wilcox, MD, Editor, CME Section
CME Credits: The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AGA Institute designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any relevant financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Instructions: Category 1 credit can be earned by reading the relevant articles and taking these CME examinations online at http://www.cghjournal. org/content/cme. Answers can be obtained online after completing the exam(s).
Objectives: See article for specific learning objective.
e26
CME ACTIVITIES
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 3
Exam 1: Patients With Nondysplastic Barrett’s Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma Test ID No.: 0125
Contact Hours: 1.0
Expiration Date: March 31, 2012
Question 1: While prior studies have shown an increased rate of esophageal cancer in patients with Barrett’s esophagus, the number of patients with progression through dysplasia to cancer is widely variable. Such rates per year in the literature vary from:
a. b. c. d.
0%–1% 0.2%–3.5% 3%–5% 3.5%– 8%
a. b. c. d. e.
Race Age Severity of heartburn Length of Barrett’s esophagus Gender
a. b. c. d.
0% 2.7% 3.48% 0.78%
a. b. c. d.
0.2% 0.38% 0.21% 3.6%
Question 2: Which of the following was the only statistically significant predictor of histologic progression to dysplasia or cancer?
Question 3: In the study by Wani et al, the incident rate for development of esophageal adenocarcinoma was:
Question 4: In the study by Wani et al, the incident rate for low-grade dysplasia per year was: